

Ladan Zand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/389052/publications.pdf>

Version: 2024-02-01

40
papers

1,183
citations

394421

19
h-index

395702

33
g-index

40
all docs

40
docs citations

40
times ranked

1512
citing authors

#	ARTICLE	IF	CITATIONS
1	Catastrophic kidney infarction. <i>Kidney International</i> , 2022, 101, 189.	5.2	0
2	A Pregnant Woman With New-Onset Hypertension and Acute Kidney Injury. <i>Kidney International Reports</i> , 2022, 7, 924-929.	0.8	2
3	Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1821-1827.	0.7	5
4	Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 104-110.	0.7	12
5	The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 840-847.	0.7	18
6	Validation of prognostic indices for short term mortality in an incident dialysis population of older adults >75. <i>PLoS ONE</i> , 2021, 16, e0244081.	2.5	6
7	CYP24A1 deficiency causing persistent hypercalciuria in a stone former. <i>Journal of Nephrology</i> , 2021, 34, 949-951.	2.0	1
8	Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1163-1173.	6.1	33
9	Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: COMMENTARY. <i>Kidney360</i> , 2021, 2, 1702-1705.	2.1	5
10	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 881-893.	0.8	39
11	Genomics Integration Into Nephrology Practice. <i>Kidney Medicine</i> , 2021, 3, 785-798.	2.0	13
12	Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2342-2353.	3.0	20
13	COVID-19 Vaccination and Glomerulonephritis. <i>Kidney International Reports</i> , 2021, 6, 2969-2978.	0.8	135
14	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1833-1839.	4.5	27
15	An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression. <i>Kidney International Reports</i> , 2020, 5, 58-65.	0.8	17
16	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020, 19, 102671.	5.8	37
17	Renal Tubular Acidosis and Immune Checkpoint Inhibitor Therapy: An Immune-Related Adverse Event of PD-1 Inhibitor – A Report of 3 Cases. <i>Kidney Medicine</i> , 2020, 2, 657-662.	2.0	26
18	Rate and Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Patients with Monoclonal Gammopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2400-2411.	6.1	33

#	ARTICLE	IF	CITATIONS
19	Acquired thoracic kidney. <i>Kidney International</i> , 2020, 97, 811.	5.2	0
20	Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. <i>American Journal of Kidney Diseases</i> , 2020, 76, 883-888.	1.9	45
21	Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. <i>Kidney International</i> , 2020, 98, 310-313.	5.2	7
22	Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series. <i>American Journal of Kidney Diseases</i> , 2020, 76, 500-510.	1.9	13
23	A Single-Center Phase 2 Open-Label Trial Evaluating the Safety and Efficacy of Daratumumab in Treatment of Patients with Monoclonal Gammopathy of Renal Significance. <i>Blood</i> , 2020, 136, 43-44.	1.4	0
24	Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. <i>Kidney International</i> , 2019, 95, 429-438.	5.2	123
25	Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 179-190.	2.9	55
26	Elevated urinary podocyte-derived extracellular microvesicles in renovascular hypertensive patients. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw077.	0.7	44
27	What are we missing in the clinical trials of focal segmental glomerulosclerosis?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i14-i21.	0.7	15
28	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i139-i145.	0.7	59
29	The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 983-1007.	3.2	29
30	The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1772-1781.	3.0	39
31	Serum Parathyroid Hormone Concentrations and Clinical Outcomes in ESRD: A Call for Targeted Clinical Trials. <i>Seminars in Dialysis</i> , 2016, 29, 184-188.	1.3	6
32	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.	4.1	76
33	Efficacy and safety of adrenocorticotrophic hormone treatment in glomerular diseases: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 387-396.	2.9	23
34	Lactate clearance and metabolic aspects of continuous high-volume hemofiltration. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 374-377.	2.9	22
35	The Case Renal dysfunction in a pregnant patient with IgA nephropathy. <i>Kidney International</i> , 2014, 85, 1477-1478.	5.2	3
36	Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 182-193.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Radiologic and Clinical Bronchiectasis Associated with Autosomal Dominant Polycystic Kidney Disease. PLoS ONE, 2014, 9, e93674.	2.5	24
38	C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series. American Journal of Kidney Diseases, 2013, 62, 506-514.	1.9	150
39	Severe Anion Gap Metabolic Acidosis From Acetaminophen Use Secondary to 5-Oxoproline (Pyroglutamic Acid) Accumulation. American Journal of the Medical Sciences, 2012, 344, 501-504.	1.1	14
40	Chronic lymphocytic leukemia and light chain proximal tubulopathy: A rare presentation of a common disease. Journal of Onco-Nephrology, 0, , 239936932210796.	0.6	1